2024
The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management
Becker R, Tantry U, Khan M, Gurbel P. The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management. Journal Of Thrombosis And Thrombolysis 2024, 1-35. PMID: 39179952, DOI: 10.1007/s11239-024-03028-4.Peer-Reviewed Original ResearchNeutrophil extracellular trapsMild to moderate illnessHost immunoinflammatory responseOptimal patient managementSARS-CoV-2SARS-CoV-2 infectionEndothelial cell inflammationVascular endothelial cellsSurveillance modalitiesClinical featuresOrgan injuryImmunoinflammatory responseMicrovascular thrombosisInflammatory signatureAtherothrombotic phenotypeCirculating monocytesChronic phasePatient managementVascular eventsAcute phaseExtracellular trapsCritical illnessThrombosisEndothelial cellsMedical literatureThe journal of thrombosis and thrombolysis: commemorating the written word in science and medicine: three decades and counting
Becker R. The journal of thrombosis and thrombolysis: commemorating the written word in science and medicine: three decades and counting. Journal Of Thrombosis And Thrombolysis 2024, 1-6. PMID: 38980568, DOI: 10.1007/s11239-024-03012-y.Peer-Reviewed Original ResearchMilvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
Tantry U, Raghavakurup L, Becker R, Singh S, Bliden K, Gurbel P. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome. Expert Opinion On Pharmacotherapy 2024, 25: 1271-1280. PMID: 39072402, DOI: 10.1080/14656566.2024.2385062.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary syndromeElevated risk of bleedingPathological thrombosisTreatment of acute coronary syndromesClinical thrombotic eventsPhysiological hemostasisRisk of bleedingPrevention of thrombosisFXIa inhibitorsBleeding riskReceptor blockersThrombotic eventsAntiplatelet therapyPlatelet antagonistsAntithrombotic efficacyFXIa inhibitionThrombosisExperimental thrombosisPatientsElevated riskLiterature searchAnticoagulationLarge-scale studiesFXIaAssessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis
Harrington J, Hellkamp A, Mahaffey K, Breithardt G, Halperin J, Hankey G, Becker R, Nessel C, Berkowitz S, Fox K, Singer D, Goodman S, Patel M, Piccini J. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal Of The American Heart Association 2024, 13: e028951. PMID: 38780169, PMCID: PMC11255646, DOI: 10.1161/jaha.122.028951.Peer-Reviewed Original ResearchAtrial fibrillationROCKET AFClinical trialsEnd pointsLow overall event ratesInternational double-blindClinical trials of interventionsRandomized clinical trialsAssessment of dayOverall event rateDouble-blindAnticoagulation trialsTreatment armsIncreased riskWarfarinTrials of interventionsClinical utilityTreatment groupsEvent ratesPatientsDAOHPoisson regressionComorbiditiesFibrillationTrialsFactor XI: structure, function and therapeutic inhibition
Ali A, Becker R. Factor XI: structure, function and therapeutic inhibition. Journal Of Thrombosis And Thrombolysis 2024, 1-14. PMID: 38622277, DOI: 10.1007/s11239-024-02972-5.Peer-Reviewed Original ResearchFactor XI inhibitorsVitamin K antagonistsEnd-stage renal diseaseFactor XITraditional anticoagulantsSafety profileInherent risk of bleedingPhase 3 clinical trialsPhase 2 studyMultiple coagulation factorsRisk of bleedingFactor XI deficiencyIntrinsic pathway of coagulationPathway of coagulationFXI inhibitorsK antagonistsOral anticoagulantsAnticoagulant therapyTherapeutic anticoagulationVenous thromboembolismPreclinical studiesAtrial fibrillationClinical endpointsRenal diseaseClinical trialsTemporal biomarker concentration patterns during the early course of acute coronary syndrome
Eggers K, Batra G, Lindahl B, Lakic T, Lindbäck J, Budaj A, Cornel J, Giannitsis E, Katus H, Storey R, Becker R, Siegbahn A, Wallentin L. Temporal biomarker concentration patterns during the early course of acute coronary syndrome. Clinical Chemistry And Laboratory Medicine 2024, 62: 1167-1176. PMID: 38341860, DOI: 10.1515/cclm-2023-1253.Peer-Reviewed Original ResearchAcute coronary syndromeST-elevation myocardial infarctionSymptom onsetNSTE-ACSHs-cTnTGDF-15Concentrations of high-sensitivity cardiac troponin TNon-ST-elevation acute coronary syndromeHigh-sensitivity cardiac troponin TPro-B-type natriuretic peptideBiomarker patternsAcute coronary syndrome patientsGrowth differentiation factor 15Cardiac troponin TC-reactive proteinPathophysiological processesBiomarker concentrationsClinically useful informationPlatelet inhibitionNatriuretic peptideHs-cTnICoronary syndromeTroponin TEarly courseAssociated with time
2023
Evaluating chest pain in patients with post COVID conditions permission to think outside of the box
Becker R. Evaluating chest pain in patients with post COVID conditions permission to think outside of the box. Journal Of Thrombosis And Thrombolysis 2023, 55: 592-603. PMID: 37052772, PMCID: PMC10098243, DOI: 10.1007/s11239-023-02808-8.Peer-Reviewed Original Research
2019
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.
Thomas M, James S, Becker R, Himmelmann A, Katus H, Cannon C, Steg P, Siegbahn A, Lakic T, Storey R, Wallentin L. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal Acute Cardiovascular Care 2019 PMID: 33609104, DOI: 10.1177/2048872619878075.Peer-Reviewed Original ResearchWhite blood cell countBaseline inflammatory markersTicagrelor compared to clopidogrelBlood cell countInflammatory markersC-reactive proteinAcute coronary syndromePrimary endpointCardiovascular deathCell countNeutrophil countClinical outcomesAcute coronary syndrome treated with ticagrelorCoronary syndromeCardiovascular benefitsN-terminal pro-brain-type natriuretic peptideInterleukin-6Increased risk of adverse cardiovascular eventsQuartile of white blood cell countComposite of cardiovascular deathAssociated with clinical outcomesRisk of adverse cardiovascular eventsLevels of inflammatory markersAcute coronary syndrome patientsPLATO study